Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina

Area of Science:

• Cardiology
• Pharmacology

Background:

• Stable angina affects millions globally, necessitating effective and well-tolerated treatments.
• Current antianginal drugs, like beta-blockers and calcium antagonists, have limitations and side effects.
• The I(f) current represents a novel target for heart rate reduction.

Purpose of the Study:

• To evaluate the efficacy and tolerability of ivabradine, a selective I(f) current inhibitor, in patients with stable angina.
• To compare ivabradine's antianginal effects with established treatments.
• To assess ivabradine's safety profile and identify patient populations who may benefit most.

Main Methods:

• A large-scale clinical development program involving over 5000 patients with stable angina.
• Randomized controlled trials comparing ivabradine to placebo and active comparators (beta-blockers, calcium antagonists).
• Assessment of antianginal efficacy endpoints and adverse event monitoring.

Main Results:

• Ivabradine demonstrated significant reductions in heart rate and improvements in exercise tolerance.
• Its antianginal efficacy was comparable to that of beta-blockers and calcium antagonists.
• Ivabradine was well-tolerated, with a favorable side effect profile, particularly regarding bradycardia and sexual dysfunction.

Conclusions:

• Ivabradine is a highly effective and well-tolerated treatment for stable angina.
• It provides a valuable therapeutic option, especially for patients intolerant to or contraindicated for beta-blockers.
• Ivabradine's selective mechanism offers pure heart rate reduction without compromising cardiac contractility or conduction.